Pharmacokinetic considerations in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis.
Toma
Meredith B
MB
University of Kentucky Chandler Medical Center, Lexington, KY, USA.
Smith
Kelly M
KM
Martin
Craig A
CA
Rapp
Robert P
RP
D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002981:Clindamycin / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D016106:Methicillin Resistance; D010019:Osteomyelitis / Q000188:drug therapy* / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus; D013752:Tetracycline / Q000493:pharmacokinetics / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000493:pharmacokinetics / Q000627:therapeutic use; D014640:Vancomycin / Q000493:pharmacokinetics / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002981:Clindamycin; D014640:Vancomycin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D013752:Tetracycline